An official website of the United States government
A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304
Trial Status: administratively complete
The purpose of this study was to provide the opportunity to the participants who
progressed on treatment arm previously in the study UTX-TGR-304 (NCT02612311) to receive
ublituximab (TG-1101) treatment in combination with umbralisib (TGR-1202).
Inclusion Criteria
Prior treatment in clinical trial UTX-TGR-304
Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria
Participants refractory to ublituximab + TGR-1202
Transformation of chronic lymphocytic leukemia (CLL) to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02656303.
Locations matching your search criteria
United States
Kansas
Kansas City
University of Kansas Cancer Center
Status: Active
Name Not Available
Overland Park
University of Kansas Cancer Center-Overland Park
Status: Active
Name Not Available
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: Active
Name Not Available
Missouri
Kansas City
University of Kansas Cancer Center - North
Status: Active
Name Not Available
The University of Kansas Cancer Center-South
Status: Active
Name Not Available
New Hampshire
Lebanon
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
